Overview

Kisspeptin refers to a family of peptides (KP-54, KP-14, KP-13, KP-10) encoded by the KISS1 gene, which are essential regulators of the hypothalamic-pituitary-gonadal (HPG) axis. Named after Hershey, Pennsylvania (where they were discovered), they function as master regulators of puberty onset, reproductive cycling, and fertility. KP-54 is the predominant form in humans. Research shows kisspeptin may also link reproductive function with metabolic status, making it a target for both fertility disorders and metabolic disease.

Mechanism of Action

Kisspeptin binds to KISS1R (GPR54), a G-protein coupled receptor coupled to Gq/11α, which activates phospholipase C and drives pulsatile GnRH release from hypothalamic neurons. This triggers downstream LH and FSH secretion from the pituitary, driving gonadal steroid production. KP54 bolus infusion in healthy women during the follicular phase causes pulsatile LH secretion. KP also acts peripherally in the ovary, testis, uterus, and pancreas, influencing local reproductive function and insulin secretion.

Potential Benefits

  • Restoration of pulsatile GnRH/LH/FSH secretion in infertility
  • Potential treatment of hypothalamic amenorrhea
  • Ovarian stimulation protocol adjunct
  • Puberty induction in idiopathic hypogonadotropic hypogonadism
  • Potential improvement of sexual desire (central effects)
  • Linkage between metabolic status and reproductive function
  • Cryoprotectant research in oocyte vitrification

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range100-300 mcg subcutaneous (Kisspeptin-10)
Beginner100 mcg subcutaneously
Intermediate150-200 mcg subcutaneously
Advanced300 mcg subcutaneously or clinical IV infusion protocol
Cycle Duration4-8 weeks; some use intermittent (2-3x/week)
Cycle Off4 weeks

Kisspeptin-54 and Kisspeptin-10 (C-terminal decapeptide) are both used; Kisspeptin-10 is more commonly available and studied. Pulsatile dosing preserves LH sensitivity. Continuous high-dose administration can paradoxically suppress GnRH via receptor desensitization.

Routes of Administration

Subcutaneous Injection High

Preferred research route; produces pulsatile LH and FSH surges; half-life ~29 minutes for Kisspeptin-54

Intramuscular Injection High

Alternative to subcutaneous; comparable LH stimulation profile

Stacking Protocols

Popular research stacks involving Kisspeptin:

HPG Axis Optimization Stack

Testosterone axis stimulation and central sexual arousal

Kisspeptin drives upstream GnRH pulsatility and LH/testosterone elevation; PT-141 activates melanocortin pathways; complementary mechanisms.

Fertility Support Stack

Hypothalamic-pituitary-gonadal axis stimulation for testosterone and fertility restoration

Used off-label in post-TRT recovery; Kisspeptin reactivates hypothalamic GnRH pulse generation; Gonadorelin provides direct GnRH receptor stimulation.

Reconstitution

Typical Vial Size2mg, 5mg (Kisspeptin-10), 10mg (Kisspeptin-54)
BAC Water1-2ml per 2mg vial
StorageRefrigerate at 2-8°C after reconstitution
Shelf Life28 days refrigerated

Need exact syringe measurements?

Amino Acid Sequence

KP-54: YNWNSFGLRF-amide and additional 44 N-terminal residues; KP-10: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2

Side Effects & Safety

  • Generally well-tolerated in clinical studies
  • Nausea at high doses
  • Hot flashes
  • Potential ovarian hyperstimulation with fertility protocols

Synergistic Compounds

The following compounds have been studied alongside Kisspeptin for potential complementary or synergistic effects:

GnRH analogsFSHPT-141

Learn More

References & Further Reading

  • [object Object]
  • [object Object]
  • [object Object]